Review
From PCP to MXE: a comprehensive review of the non‐medical use of dissociative drugs
Abstract
PCP or phencyclidine was discovered in 1956 and soon became a popular street drug. Dissociatives including PCP, ketamine, and dextromethorphan have been used non‐medically for their mind‐altering effects for over 60 years. Many of these compounds have also been used clinically and in legitimate research. At least 14 derivatives of PCP were sold for non‐medical and illict use from the late 1960s until the 1990s. With the advent of the Internet, the drug market underwent a dramatic evolution. While initially gray‐market chemical vendors offering dextromethorphan and ketamine thrived, most recently the market has shifted to legal high and online‐based research chemical vendors. Starting with the first dissociative research chemical, 4‐MeO‐PCP in 2008, the dissociative research chemical market has rapidly evolved and currently comprises at least 12 dissociatives, almost half of which were unknown in the scientific literature prior to their introduction. Several of these, including methoxetamine, have reached widespread use internationally. A historical account of non‐medical use of over 30 dissociative compounds was compiled from a diverse collection of sources. The first complete portrait of this underground market is presented along with the relevant legal, technological, and scientific developments which have driven its evolution. Copyright © 2014 John Wiley & Sons, Ltd.
Citing Literature
Number of times cited: 76
- Simon Elliott, Roumen Sedefov and Michael Evans‐Brown, Assessing the toxicological significance of new psychoactive substances in fatalities, Drug Testing and Analysis, 10, 1, (120-126), (2017).
- Maiko Kusano, Kei Zaitsu, Kentaro Taki, Kazuaki Hisatsune, Jun'ichi Nakajima, Takako Moriyasu, Tomomi Asano, Yumi Hayashi, Hitoshi Tsuchihashi and Akira Ishii, Fatal intoxication by 5F–ADB and diphenidine: Detection, quantification, and investigation of their main metabolic pathways in humans by LC/MS/MS and LC/Q‐TOFMS, Drug Testing and Analysis, 10, 2, (284-293), (2017).
- Tristan Colestock, Jason Wallach, Matt Mansi, Nadine Filemban, Hamilton Morris, Simon P. Elliott, Folker Westphal, Simon D. Brandt and Adeboye Adejare, Syntheses, analytical and pharmacological characterizations of the ‘legal high’ 4‐[1‐(3‐methoxyphenyl)cyclohexyl]morpholine (3‐MeO‐PCMo) and analogues, Drug Testing and Analysis, 10, 2, (272-283), (2017).
- Felix Betzler and Tomislav Majić, Dissoziativa, Handbuch Psychoaktive Substanzen, 10.1007/978-3-642-55125-3_48, (683-699), (2017).
- Dino Luethi, Marius C. Hoener and Matthias E. Liechti, Effects of the new psychoactive substances diclofensine, diphenidine, and methoxphenidine on monoaminergic systems, European Journal of Pharmacology, 10.1016/j.ejphar.2017.12.012, 819, (242-247), (2018).
- Tiziano Acciavatti, Matteo Lupi, Rita Santacroce, Andrea Aguglia, Luigi Attademo, Laura Bandini, Paola Ciambrone, Giulia Lisi, Giovanni Migliarese, Federica Pinna, Diego Quattrone, Michele Ribolsi, Maria Salvina Signorelli, Salvatore Calò, Fabrizio Schifano, Massimo Giannantonio and Giovanni Martinotti, Novel psychoactive substance consumption is more represented in bipolar disorder than in psychotic disorders: A multicenter‐observational study, Human Psychopharmacology: Clinical and Experimental, 32, 3, (2017).
- Enrico Gerace, Elena Bovetto, Daniele Di Corcia, Marco Vincenti and Alberto Salomone, A Case of Nonfatal Intoxication Associated with the Recreational use of Diphenidine, Journal of Forensic Sciences, 62, 4, (1107-1111), (2017).
- M T Zanda, P Fadda, S Antinori, M Di Chio, W Fratta, C Chiamulera and L Fattore, Methoxetamine affects brain processing involved in emotional response in rats, British Journal of Pharmacology, 174, 19, (3333-3345), (2017).
- Serge Weis and Andreas Büttner, Neurotoxicology and drug-related disorders, Neuropathology, 10.1016/B978-0-12-802395-2.00014-6, (181-192), (2017).
- Basile Chrétien, Joanna Bourgine, Léa Hamel Sénécal, Marie Bretaudeau-Deguigne, Davis Boels, Véronique Lelong-Boulouard and Reynald Le Boisselier, Severe Serotonin Syndrome in an Autistic New Psychoactive Substance User After Consumption of Pills Containing Methoxphenidine and α-Methyltryptamine, Journal of Clinical Psychopharmacology, (1), (2017).
- Lan-Gui Xie and Darren J. Dixon, Tertiary amine synthesis via reductive coupling of amides with Grignard reagents, Chem. Sci., 10.1039/C7SC03613B, 8, 11, (7492-7497), (2017).
- Ricardo P. Garay and George T. Grossberg, AVP-786 for the treatment of agitation in dementia of the Alzheimer’s type, Expert Opinion on Investigational Drugs, 26, 1, (121), (2017).
- Anna Johansson, Daniel Lindstedt, Markus Roman, Gunilla Thelander, Elisabet I. Nielsen, Ulrica Lennborn, Håkan Sandler, Sten Rubertsson, Johan Ahlner, Robert Kronstrand and Fredrik C. Kugelberg, A non-fatal intoxication and seven deaths involving the dissociative drug 3-MeO-PCP, Forensic Science International, 275, (76), (2017).
- Yan Du, Li Du, Jie Cao, Christian Hölscher, Yongming Feng, Hongliang Su, Yujin Wang and Ke-Ming Yun, Levo-tetrahydropalmatine inhibits the acquisition of ketamine-induced conditioned place preference by regulating the expression of ERK and CREB phosphorylation in rats, Behavioural Brain Research, 317, (367), (2017).
- Monika Zidkova, Tomas Hlozek, Martin Balik, Ondrej Kopecky, Pavel Tesinsky, Jan Svanda and Marie Anna Balikova, Two Cases of Non-fatal Intoxication with a Novel Street Hallucinogen: 3-Methoxy-Phencyclidine, Journal of Analytical Toxicology, 41, 4, (350), (2017).
- Barry K. Logan, Amanda L.A. Mohr, Melissa Friscia, Alex J. Krotulski, Donna M. Papsun, Sherri L. Kacinko, Jeri D. Ropero-Miller and Marilyn A. Huestis, Reports of Adverse Events Associated with Use of Novel Psychoactive Substances, 2013–2016: A Review, Journal of Analytical Toxicology, 10.1093/jat/bkx031, 41, 7, (573-610), (2017).
- Tatiana O. Kolesnikova, Sergey L. Khatsko, Vadim A. Shevyrin, Yuri Yu Morzherin and Allan V. Kalueff, Effects of a non-competitive N-methyl-d-aspartate (NMDA) antagonist, tiletamine, in adult zebrafish, Neurotoxicology and Teratology, 59, (62), (2017).
- James H. Ho and Paul I. Dargan, Arylcyclohexamines: Ketamine, Phencyclidine, and Analogues, Critical Care Toxicology, 10.1007/978-3-319-17900-1_124, (1439-1484), (2017).
- Andreas Büttner, The neuropathology of drug abuse, Current Opinion in Behavioral Sciences, 13, (8), (2017).
- Michael D. Berquist, William S. Hyatt, Jonathan Bauer-Erickson, Brenda M. Gannon, Andrew P. Norwood and William E. Fantegrossi, Phencyclidine-like in vivo effects of methoxetamine in mice and rats, Neuropharmacology, (2017).
- Elisabetta Bertol, Jennifer Pascali, Diego Palumbo, Valeria Catalani, Maria Grazia Di Milia, Alessia Fioravanti, Francesco Mari and Fabio Vaiano, 3-MeO-PCP intoxication in two young men: First in vivo detection in Italy, Forensic Science International, 274, (7), (2017).
- B. Jurasek, M. Himl, R. Jurok, K. Hajkova, A. Vobinuskova, P. Rezanka and M. Kuchar, Synthesis of methoxetamine, its metabolites and deuterium labelled analog as analytical standards and their HPLC and chiral capillary electrophoresis separation, RSC Advances, 7, 89, (56691), (2017).
- Heather Kang, Pojeong Park, Zuner A. Bortolotto, Simon D. Brandt, Tristan Colestock, Jason Wallach, Graham L. Collingridge and David Lodge, Ephenidine: A new psychoactive agent with ketamine-like NMDA receptor antagonist properties, Neuropharmacology, 10.1016/j.neuropharm.2016.08.004, 112, (144-149), (2017).
- D. Fabregat-Safont, X. Carbón, M. Ventura, I. Fornís, E. Guillamón, J. V. Sancho, F. Hernández and M. Ibáñez, Updating the list of known opioids through identification and characterization of the new opioid derivative 3,4-dichloro-N-(2-(diethylamino)cyclohexyl)-N-methylbenzamide (U-49900), Scientific Reports, 10.1038/s41598-017-06778-9, 7, 1, (2017).
- Felix Betzler and Tomislav Majić, Dissoziativa, Handbuch Psychoaktive Substanzen, 10.1007/978-3-642-55214-4_48-1, (1-22), (2017).
- M.T. Zanda and L. Fattore, Novel Psychoactive Substances, Addictive Substances and Neurological Disease, 10.1016/B978-0-12-805373-7.00029-3, (341-353), (2017).
- Piotr Popik, Małgorzata Hołuj, Tomasz Kos, Gabriel Nowak, Tadeusz Librowski and Kinga Sałat, Comparison of the Psychopharmacological Effects of Tiletamine and Ketamine in Rodents, Neurotoxicity Research, 32, 4, (544), (2017).
- William Champeau, Céline Eiden, Julien Gambier and Hélène Peyriere, Methoxphenidine Use Disorder, Journal of Clinical Psychopharmacology, 37, 3, (376), (2017).
- J. Maixner, B. Jurásek, M. Himl, M. Kuchař and M. Babor, X-ray powder diffraction data for methoxetamine hydrochloride, C15H22ClNO2, Powder Diffraction, 32, 04, (265), (2017).
- Christie Mitchell-Mata, Brittany Thomas, Brianna Peterson and Fiona Couper, Two Fatal Intoxications Involving 3-Methoxyphencyclidine, Journal of Analytical Toxicology, 41, 6, (503), (2017).
- Anna Fantinati, Andrea Ossato, Sara Bianco, Isabella Canazza, Fabio De Giorgio, Claudio Trapella and Matteo Marti, 1‐cyclohexyl‐x‐methoxybenzene derivatives, novel psychoactive substances seized on the internet market. Synthesis and in vivo pharmacological studies in mice, Human Psychopharmacology: Clinical and Experimental, 32, 3, (2017).
- Jason Wallach, Tristan Colestock, Brian Cicali, Simon P. Elliott, Pierce V. Kavanagh, Adeboye Adejare, Nicola M. Dempster and Simon D. Brandt, Syntheses and analytical characterizations of N‐alkyl‐arylcyclohexylamines, Drug Testing and Analysis, 8, 8, (801-815), (2015).
- Carina S. D. Wink, Julian A. Michely, Andrea Jacobsen‐Bauer, Josef Zapp and Hans H. Maurer, Diphenidine, a new psychoactive substance: metabolic fate elucidated with rat urine and human liver preparations and detectability in urine using GC‐MS, LC‐MSn, and LC‐HR‐MSn, Drug Testing and Analysis, 8, 10, (1005-1014), (2016).
- Gavin McLaughlin, Noreen Morris, Pierce V. Kavanagh, John D. Power, John O'Brien, Brian Talbot, Simon P. Elliott, Jason Wallach, Khoa Hoang, Hamilton Morris and Simon D. Brandt, Test purchase, synthesis, and characterization of 2‐methoxydiphenidine (MXP) and differentiation from its meta‐ and para‐substituted isomers, Drug Testing and Analysis, 8, 1, (98-109), (2015).
- Mark Rafter, Kevin CF. Fone and Paula M. Moran, Glutamate Pharmacological Models Relevant to Schizophrenia and Psychosis, Modeling the Psychopathological Dimensions of Schizophrenia - From Molecules to Behavior, 10.1016/B978-0-12-800981-9.00010-9, (139-174), (2016).
- Pierre M. Geyer, Matthew C. Hulme, Joseph P. B. Irving, Paul D. Thompson, Ryan N. Ashton, Robert J. Lee, Lucy Johnson, Jack Marron, Craig E. Banks and Oliver B. Sutcliffe, Guilty by dissociation—development of gas chromatography–mass spectrometry (GC-MS) and other rapid screening methods for the analysis of 13 diphenidine-derived new psychoactive substances (NPSs), Analytical and Bioanalytical Chemistry, 10.1007/s00216-016-9969-y, 408, 29, (8467-8481), (2016).
- Mary T. Zanda, Paola Fadda, Cristiano Chiamulera, Walter Fratta and Liana Fattore, Methoxetamine, a novel psychoactive substance with serious adverse pharmacological effects, Behavioural Pharmacology, 10.1097/FBP.0000000000000241, 27, 6, (489-496), (2016).
- Colin Davidson and Fabrizio Schifano, The potential utility of some legal highs in CNS disorders, Progress in Neuro-Psychopharmacology and Biological Psychiatry, 64, (267), (2016).
- Rex Pui Kin Lam, Wai Lam Yip, Matthew Sik Hon Tsui, Sau Wah Ng, Chor Kwan Ching and Tony Wing Lai Mak, Severe rhabdomyolysis and acute kidney injury associated with methoxphenidine, Clinical Toxicology, 54, 5, (464), (2016).
- Adam L. Halberstadt, Natalia Slepak, James Hyun, Mahalah R. Buell and Susan B. Powell, The novel ketamine analog methoxetamine produces dissociative-like behavioral effects in rodents, Psychopharmacology, 233, 7, (1215), (2016).
- Sandra Lavelle, Designer Drugs and the Impact on the Adolescent User, Archives of Psychiatric Nursing, 30, 3, (447), (2016).
- Cristiano Chiamulera, Federica Armani, Anna Mutti and Liana Fattore, The ketamine analogue methoxetamine generalizes to ketamine discriminative stimulus in rats, Behavioural Pharmacology, 27, (204), (2016).
- Erica Bakota, Crystal Arndt, Amelia A. Romoser and Stephen K. Wilson, Fatal Intoxication Involving 3-MeO-PCP: A Case Report and Validated Method, Journal of Analytical Toxicology, 40, 7, (504), (2016).
- Ruri Kikura-Hanajiri, New Designer Drugs in Japan, Neuropathology of Drug Addictions and Substance Misuse, 10.1016/B978-0-12-800212-4.00097-2, (1055-1065), (2016).
- James H. Ho and Paul I. Dargan, Arylcyclohexamines (Ketamine, Phencyclidine, and Analogues), Critical Care Toxicology, 10.1007/978-3-319-20790-2_124-1, (1-46), (2016).
- Sean Sassano‐Higgins, Dave Baron, Grace Juarez, Neevon Esmaili and Mark Gold, A REVIEW OF KETAMINE ABUSE AND DIVERSION, Depression and Anxiety, 33, 8, (718-727), (2016).
- Shruti Beharry and Simon Gibbons, An overview of emerging and new psychoactive substances in the United Kingdom, Forensic Science International, 10.1016/j.forsciint.2016.08.013, 267, (25-34), (2016).
- José A. Fernández-Salas, Alexander P. Pulis and David J. Procter, Metal-free C–H thioarylation of arenes using sulfoxides: a direct, general diaryl sulfide synthesis, Chemical Communications, 52, 83, (12364), (2016).
- Rachel R. Horsley, Eva Lhotkova, Katerina Hajkova, Bronislav Jurasek, Martin Kuchar and Tomas Palenicek, Detailed pharmacological evaluation of methoxetamine (MXE), a novel psychoactive ketamine analogue—Behavioural, pharmacokinetic and metabolic studies in the Wistar rat, Brain Research Bulletin, 126, (102), (2016).
- Anna Mutti, Sonia Aroni, Paola Fadda, Laura Padovani, Laura Mancini, Roberto Collu, Anna Lisa Muntoni, Liana Fattore and Cristiano Chiamulera, The ketamine-like compound methoxetamine substitutes for ketamine in the self-administration paradigm and enhances mesolimbic dopaminergic transmission, Psychopharmacology, 233, 12, (2241), (2016).
- S.E. Lukas, Substance Abuse: Drugs, Encyclopedia of Mental Health, 10.1016/B978-0-12-397045-9.00098-7, (249-262), (2016).
- Snehal V. Ingle and Kaustubh A. Joshi, Electron density topography based model to explore N-methyl- d -aspartate receptor channel blockers, Chemical Physics Letters, 648, (53), (2016).
- Evelyn Hearne and Marie Claire Van Hout, “Trip-Sitting” in the Black Hole: A Netnographic Study of Dissociation and Indigenous Harm Reduction, Journal of Psychoactive Drugs, 48, 4, (233), (2016).
- Jason Wallach, Heather Kang, Tristan Colestock, Hamilton Morris, Zuner A. Bortolotto, Graham L. Collingridge, David Lodge, Adam L. Halberstadt, Simon D. Brandt, Adeboye Adejare and Joohyung Lee, Pharmacological Investigations of the Dissociative ‘Legal Highs’ Diphenidine, Methoxphenidine and Analogues, PLOS ONE, 11, 6, (e0157021), (2016).
- Andreas Büttner, Neuropathological Studies in Polydrug Abusers, Neuropathology of Drug Addictions and Substance Misuse, 10.1016/B978-0-12-800634-4.00087-1, (884-889), (2016).
- Jason Wallach, Pierce V. Kavanagh, Gavin McLaughlin, Noreen Morris, John D. Power, Simon P. Elliott, Marion S. Mercier, David Lodge, Hamilton Morris, Nicola M. Dempster and Simon D. Brandt, Preparation and characterization of the ‘research chemical’ diphenidine, its pyrrolidine analogue, and their 2,2‐diphenylethyl isomers, Drug Testing and Analysis, 7, 5, (358-367), (2014).
- D Lodge and M S Mercier, Ketamine and phencyclidine: the good, the bad and the unexpected, British Journal of Pharmacology, 172, 17, (4254-4276), (2015).
- Fabrizio Schifano, Laura Orsolini, G. Duccio Papanti and John M. Corkery, Novel psychoactive substances of interest for psychiatry, World Psychiatry, 14, 1, (15-26), (2015).
- François Chavant, Alexandra Boucher, Reynald Le Boisselier, Sylvie Deheul and Danièle Debruyne, Nouvelles drogues de synthèse en addictovigilance, Thérapie, 70, 2, (167), (2015).
- Agnieszka Wiesner, Aleksandra Tyl and Jolanta B. Zawilska, Metoksetamina – nowy związek psychoaktywny („dopalacz”) o silnym działaniu psychodysleptycznym, Alcoholism and Drug Addiction, 28, 2, (131), (2015).
- Eman H. El-Naby and Ayman H. Kamel, Potential transducers based man-tailored biomimetic sensors for selective recognition of dextromethorphan as an antitussive drug, Materials Science and Engineering: C, 54, (217), (2015).
- Chrislean Jun Botanas, June Bryan de la Peña, Irene Joy dela Peña, Reinholdgher Tampus, Robin Yoon, Hee Jin Kim, Yong Sup Lee, Choon Gon Jang and Jae Hoon Cheong, Methoxetamine, a ketamine derivative, produced conditioned place preference and was self-administered by rats: Evidence of its abuse potential, Pharmacology Biochemistry and Behavior, 133, (31), (2015).
- David Baumeister, Luis M. Tojo and Derek K. Tracy, Legal highs: staying on top of the flood of novel psychoactive substances, Therapeutic Advances in Psychopharmacology, 5, 2, (97), (2015).
- Anders Helander, Olof Beck and Matilda Bäckberg, Intoxications by the dissociative new psychoactive substances diphenidine and methoxphenidine, Clinical Toxicology, 10.3109/15563650.2015.1033630, 53, 5, (446-453), (2015).
- Steven Karch and Olaf Drummer, Dissociative Anesthetics, Karch's Pathology of Drug Abuse, Fifth Edition, 10.1201/b18962-7, (697-754), (2015).
- S. P. Elliott, S. D. Brandt, J. Wallach, H. Morris and P. V. Kavanagh, First Reported Fatalities Associated with the 'Research Chemical' 2-Methoxydiphenidine, Journal of Analytical Toxicology, 10.1093/jat/bkv006, 39, 4, (287-293), (2015).
- Santiago Nogué, Miguel Galicia, Marina Parra and Jordi To-Figueras, Methoxetamine-associated emergencies. First Spanish descriptions of this new drug, Medicina Clínica (English Edition), 145, 9, (416), (2015).
- R. Giorgetti, D. Marcotulli, A. Tagliabracci and F. Schifano, Effects of ketamine on psychomotor, sensory and cognitive functions relevant for driving ability, Forensic Science International, 252, (127), (2015).
- Matilda Bäckberg, Olof Beck and Anders Helander, Phencyclidine analog use in Sweden—intoxication cases involving 3-MeO-PCP and 4-MeO-PCP from the STRIDA project, Clinical Toxicology, 53, 9, (856), (2015).
- François Chavant, Alexandra Boucher, Reynald Le Boisselier, Sylvie Deheul and Danièle Debruyne, New Synthetic Drugs in Addictovigilance, Thérapie, 70, 2, (179), (2015).
- Santiago Nogué, Miguel Galicia, Marina Parra and Jordi To-Figueras, Urgencias asociadas al consumo de metoxetamina. Primeras descripciones en España de esta nueva droga, Medicina Clínica, 145, 9, (416), (2015).
- Simon D. Brandt, Leslie A. King and Michael Evans‐Brown, The new drug phenomenon, Drug Testing and Analysis, 6, 7-8, (587-597), (2014).
- Katharina E. Hofer, Colette Degrandi, Daniel M. Müller, Ursina Zürrer-Härdi, Schirin Wahl, Christine Rauber-Lüthy and Alessandro Ceschi, Acute toxicity associated with the recreational use of the novel dissociative psychoactive substance methoxphenidine, Clinical Toxicology, 52, 10, (1288), (2014).
- Jolanta B. Zawilska, Methoxetamine – a novel recreational drug with potent hallucinogenic properties, Toxicology Letters, 230, 3, (402), (2014).
- Zurina Hassan, Oliver G. Bosch, Darshan Singh, Suresh Narayanan, B. Vicknasingam Kasinather, Erich Seifritz, Johannes Kornhuber, Boris B. Quednow and Christian P. Müller, Novel Psychoactive Substances—Recent Progress on Neuropharmacological Mechanisms of Action for Selected Drugs, Frontiers in Psychiatry, 10.3389/fpsyt.2017.00152, 8, (2017).
- Camila Sanz and Enzo Tagliazucchi, The Experience Elicited by Hallucinogens Presents the Highest Similarity to Dreaming within a Large Database of Psychoactive Substance Reports, Frontiers in Neuroscience, 10.3389/fnins.2018.00007, 12, (2018).
